Display Settings:

Format

Send to:

Choose Destination

    Breast Cancer Res Treat. 2009 Oct;117(3):571-5. Epub 2009 Jan 20.

    Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.

    Lynn Henry N, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics Investigators.

    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA, norahh@med.umich.edu.

    Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.

    PMID: 19153830 [PubMed - in process]

    PMCID: 2746261

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read

    Patient drug information

    • Tamoxifen (Nolvadex®)

      Your doctor has prescribed tamoxifen for you. Tamoxifen comes as a tablet to take by mouth.